CO2023014204A2 - Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7) - Google Patents

Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7)

Info

Publication number
CO2023014204A2
CO2023014204A2 CONC2023/0014204A CO2023014204A CO2023014204A2 CO 2023014204 A2 CO2023014204 A2 CO 2023014204A2 CO 2023014204 A CO2023014204 A CO 2023014204A CO 2023014204 A2 CO2023014204 A2 CO 2023014204A2
Authority
CO
Colombia
Prior art keywords
nek7
inhibitors
never
compounds
related kinase
Prior art date
Application number
CONC2023/0014204A
Other languages
English (en)
Inventor
John Sai Keong Kauwe Iii
Alexis Henri Abel Mollard
David James Bearss
Original Assignee
Halia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Halia Therapeutics Inc filed Critical Halia Therapeutics Inc
Publication of CO2023014204A2 publication Critical patent/CO2023014204A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporcionan compuestos que tienen actividad como inhibidores de NEK7. Los compuestos tienen la Estructura (I): (I) o una sal, estereoisómero o profármaco farmacéuticamente aceptable del mismo, en donde A, X, Y, Z, R1, R 2, R3 y n son como se definen en la presente. También se proporcionan métodos asociados con la preparación y uso de estos compuestos, composiciones farmacéuticas que comprenden estos compuestos y métodos para modular la actividad del inflamasoma NLRP3.
CONC2023/0014204A 2021-04-05 2023-10-24 Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7) CO2023014204A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163170708P 2021-04-05 2021-04-05
US202163185282P 2021-05-06 2021-05-06
PCT/US2022/023443 WO2022216680A1 (en) 2021-04-05 2022-04-05 Nek7 inhibitors

Publications (1)

Publication Number Publication Date
CO2023014204A2 true CO2023014204A2 (es) 2023-11-10

Family

ID=81448482

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0014204A CO2023014204A2 (es) 2021-04-05 2023-10-24 Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7)

Country Status (11)

Country Link
US (1) US20240317758A1 (es)
EP (1) EP4320127A1 (es)
JP (1) JP2024513227A (es)
KR (1) KR20230175222A (es)
AU (1) AU2022255486A1 (es)
BR (1) BR112023019435A2 (es)
CA (1) CA3214042A1 (es)
CO (1) CO2023014204A2 (es)
IL (1) IL307258A (es)
MX (1) MX2023011464A (es)
WO (1) WO2022216680A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4146348T (lt) 2020-05-08 2024-10-10 Halia Therapeutics, Inc. Nek7 kinazės inhibitoriai
US20240158394A1 (en) * 2022-09-14 2024-05-16 Halia Therapeutics, Inc. Nek7 inhibitors
JP2024120882A (ja) * 2023-02-24 2024-09-05 日本たばこ産業株式会社 置換ピラゾロピリミジン化合物及びその医薬用途
WO2024177126A1 (ja) * 2023-02-24 2024-08-29 日本たばこ産業株式会社 ６－アルコキシピラゾロピリミジン化合物及びその医薬用途
WO2024196786A1 (en) * 2023-03-17 2024-09-26 Ventus Therapeutics U.S., Inc. Urea derivatives for inhibiting nlrp3 and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US7902356B2 (en) 2004-12-17 2011-03-08 Eli Lilly And Company Thiazolopyridinone derivates as MCH receptor antagonists
CA2666116A1 (en) 2006-10-16 2008-04-24 Novartis Ag Phenylacetamides useful as protein kinase inhibitors
EP2170871A2 (en) 2007-06-26 2010-04-07 GlaxoSmithKline LLC Processes for preparing benzimidazole thiophenes
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
ES2658395T3 (es) 2012-04-04 2018-03-09 Rigel Pharmaceuticals, Inc. Inhibidores de proteína cinasa C y usos de los mismos
CN103420977B (zh) 2012-05-16 2016-06-22 上海医药集团股份有限公司 具有抗肿瘤活性的乙炔衍生物
MX2015000830A (es) 2012-07-18 2015-10-26 Sunshine Lake Pharma Co Ltd Derivados heterociclicos nitrogenosos y su aplicacion en farmacos.
US8859553B2 (en) 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
ES2755772T3 (es) 2012-11-07 2020-04-23 Nerviano Medical Sciences Srl Pirimidinil y piridinilpirrolopiridinonas sustituidas, proceso para su preparación y su uso como inhibidores de cinasas
US9682083B2 (en) 2013-05-14 2017-06-20 Nerviano Medical Sciences S.R.L. Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
US9670203B2 (en) 2013-06-28 2017-06-06 Beigene, Ltd. Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors
KR101900584B1 (ko) 2014-02-03 2018-09-19 콰드리가 바이오사이언시스 인코포레이티드 화학치료제로서의 베타-치환된 베타-아미노산 및 유사체
WO2016029776A1 (en) 2014-08-26 2016-03-03 Astar Biotech Llc Protein kinase inhibitors
CN105837575B (zh) 2015-01-13 2019-01-15 四川大学 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途
US10464922B2 (en) 2015-12-30 2019-11-05 Nqp 1598, Ltd. Metalloenzyme inhibitor compounds
CN107513068A (zh) 2016-06-16 2017-12-26 中国科学院上海药物研究所 一种具有fgfr抑制活性的新型化合物及其制备和应用
WO2017222285A1 (ko) 2016-06-20 2017-12-28 재단법인 대구경북첨단의료산업진흥재단 신규한 이미다조피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
RU2753520C2 (ru) 2016-06-21 2021-08-17 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные n-(замещенный фенил)-сульфонамида в качестве ингибиторов киназы
EP3296297A1 (en) 2016-09-15 2018-03-21 Centre National De La Recherche Scientifique Benzimidazol derivatives for treating filovirus infection
WO2018102751A1 (en) 2016-12-02 2018-06-07 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
WO2018215668A1 (en) 2017-05-26 2018-11-29 Glenmark Pharmaceuticals S.A. Novel inhibitors of map4k1
WO2018222917A1 (en) 2017-06-01 2018-12-06 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
AU2018327170B2 (en) 2017-08-31 2021-03-11 Daiichi Sankyo Company, Limited Novel method for producing antibody-drug conjugate
JP7328987B6 (ja) * 2018-04-05 2023-10-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｉ型ｉｒａｋ阻害剤としてのヘテロアリール化合物及びその使用
WO2019196812A1 (zh) 2018-04-09 2019-10-17 上海科技大学 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用
WO2019200120A1 (en) 2018-04-11 2019-10-17 Lycera Corporation Dihydroisoquinoline-2(1h)-carboxamide and related compounds and their use in treating medical conditions
CN112243439A (zh) 2018-06-13 2021-01-19 百济神州有限公司 作为hpk1抑制剂的吡咯并[2,3-b]吡啶或吡咯并[2,3-b]吡嗪及其用途
CN111377907B (zh) 2018-12-26 2023-03-28 杭州百新生物医药科技有限公司 一种多取代苯氨基嘧啶衍生物及其制备方法和用途
CN111646995B (zh) * 2019-03-04 2023-03-21 四川大学 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途
WO2020206583A1 (en) 2019-04-08 2020-10-15 Qilu Regor Therapeutics Inc. Kinase inhibitors and uses thereof
JP7353682B2 (ja) * 2019-09-26 2023-10-02 深▲チェン▼市塔吉瑞生物医薬有限公司 置換された縮合芳香環誘導体、その組成物、およびそれらの使用
CN114761000A (zh) 2019-10-01 2022-07-15 金翅雀生物公司 Cdk5的取代的1,6-萘啶抑制剂
CN115210226B (zh) 2020-02-20 2024-01-09 广州白云山医药集团股份有限公司白云山制药总厂 喹啉类化合物
WO2021226547A2 (en) 2020-05-08 2021-11-11 Halia Therapeutics, Inc. Targeted nek7 inhibition for modulation of the nlrp3 inflammasome
CN113717156B (zh) 2020-05-25 2023-05-09 南京红云生物科技有限公司 Egfr抑制剂、其制备方法及用途
GB202010464D0 (en) 2020-07-08 2020-08-19 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Also Published As

Publication number Publication date
JP2024513227A (ja) 2024-03-22
MX2023011464A (es) 2023-10-19
BR112023019435A2 (pt) 2023-10-24
WO2022216680A1 (en) 2022-10-13
EP4320127A1 (en) 2024-02-14
KR20230175222A (ko) 2023-12-29
IL307258A (en) 2023-11-01
CA3214042A1 (en) 2022-10-13
US20240317758A1 (en) 2024-09-26
AU2022255486A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
CO2023014204A2 (es) Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7)
CO2022017622A2 (es) Inhibidores de quinasa nek7
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
CO2019011762A2 (es) Compuestos que inhiben la proteína mcl-1
CO2022019131A2 (es) Inhibidores de la quinasa nek7
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
GT200500325A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa
CO6571916A2 (es) Derivados de arilmetoxi isoindolina y composiciones que lo comprenden y métodos para utilizar los mismos
CL2022002695A1 (es) Inhibidores de rip1k
AR063096A1 (es) Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina
CO2024007129A2 (es) Inhibidores de lisina acetiltransferasa 6a (kat6a) y usos de los mismos
MX2020003993A (es) Derivados de bencimidazol y sus usos.
CL2020003380A1 (es) Compuestos que aumentan la actividad del proteosoma.
PE20210550A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CL2022001692A1 (es) Compuestos activos frente a receptores nucleares
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
CO2023012903A2 (es) Derivados de pirimidina útiles como inhibidores de la proteína cinasa de repetición 2 rica en leucina (lrrk2)
PE20191819A1 (es) Analogos de deutetrabenazina, su preparacion y uso
DOP2023000194A (es) Moduladores de sting (estimulador de genes de interferón)
UY39625A (es) Derivados tricíclicos útiles como inhibidores de parp7
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1